series-a
Stage
About
Vironexis is a clinical-stage biotechnology company developing the first in vivo protein engineering platform using AAV gene therapy to enable continuous, off-the-shelf T-cell engager expression for cancer and immune disorder treatments.
Explore Vironexis's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.